Cognition Therapeutics is advancing CT1812 through a Phase 1 clinical trial aimed at assessing its pharmacokinetics in older healthy volunteers. The focus on Alzheimer's disease positions CT1812 within a significant and growing market, as the global Alzheimer's therapeutics market is projected to reach $20 billion by 2025. Given the increasing prevalence of Alzheimer's and the limited efficacy of current treatments, CT1812 could represent a novel therapeutic option. However, the competitive landscape includes established players and emerging biotech firms, necessitating a robust strategy for differentiation and market entry. Diligence should focus on the safety profile and pharmacokinetic data to gauge potential for further development.